Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Gynecologic oncology

Understanding Your Cervical Cancer Diagnosis & Biology

At a Glance

Most cervical cancers are linked to persistent high-risk HPV, but an HPV result does not reveal when infection began or assign blame. Your pathology report identifies the cancer’s cell type, which helps doctors understand its behavior and plan care.

Receiving a cervical cancer diagnosis is a life-altering moment that often brings a complex mix of fear, confusion, and sometimes even a sense of relief after months of unexplained symptoms [1]. It is common to feel overwhelmed by the technical language of pathology reports while also navigating the emotional weight of a diagnosis linked to a virus like HPV [2].

Understanding the biology of your diagnosis is an empowering first step. While the precancerous changes that lead to most cervical cancers develop slowly over years, a confirmed invasive cancer requires timely staging and medical action. Gathering information and seeking a second opinion are reasonable, but they should not cause avoidable delay in your treatment planning [3].

The Role of HPV: Clearing the Stigma

Almost all cervical cancers (about 90–95%) are associated with a persistent infection with high-risk HPV (Human Papillomavirus) [4]. It is vital to understand that HPV is an extremely common virus that most adults will be exposed to at some point in their lives [5].

  • It is not your fault: An HPV-related diagnosis is not a reflection of your lifestyle or choices. HPV infections generally clear on their own within one to two years. However, when the infection persists, it can lead to cellular changes. A positive HPV result cannot tell you when the infection was acquired or who transmitted it; the virus can remain latent for years before causing problems [2][5].
  • The “Driver” of Cancer: Most HPV-associated cancers develop after the virus produces two proteins, E6 and E7. These proteins turn off your cells’ natural “brakes” (tumor suppressor proteins like p53 and Rb), allowing cells to grow uncontrollably [6][7].
  • A Slow Process: The progression from infection to cancer usually takes many years, and cancer typically develops when a high-risk strain (most commonly HPV 16 or HPV 18) stays active in the cervical cells [3][8].

Understanding Your Cancer Type

Your pathology report will identify the specific “cell type” or histology of the cancer. This tells your doctors which cells the cancer started in and helps them predict how it might behave.

Common Types (HPV-Associated)

The vast majority of cases fall into these categories, which are almost always linked to HPV:

  • Squamous Cell Carcinoma (SCC): This is the most common type, accounting for 65–75% of cases. It begins in the thin, flat cells lining the outer part of the cervix [9][10].
  • Adenocarcinoma: Accounting for about 10–25% of cases, this type starts in the glandular cells that produce mucus in the cervical canal [9][11].
  • Adenosquamous Carcinoma: A less common type that contains both squamous and glandular cancer cells [12].

Aggressive and Rare Types

A small percentage of cervical cancers exhibit different biological behavior and may require specialized care [4][13].

  • Neuroendocrine Carcinoma: An extremely rare (less than 2%) but aggressive type that can grow quickly and may require different chemotherapy combinations. While it behaves aggressively, it is still frequently associated with high-risk HPV (often HPV 18) [14][15].
  • Gastric-type Adenocarcinoma: A rare and often more aggressive subtype that is typically HPV-independent (not caused by the virus) and does not respond as well to standard treatments as the usual types [16][17].
  • Other Rare Types: These include clear-cell, mesonephric, and endometrioid adenocarcinomas, which have distinct biological profiles and often require specialized pathology review [18][19].

Navigating the Emotions of Diagnosis

It is normal to experience “stigma” or a sense of shame because HPV is sexually transmitted. This stigma can make it harder to talk about your diagnosis with partners, friends, or even your medical team [1][2].

Current medical guidelines emphasize that psychosocial support—such as counseling or support groups—is a vital part of your care [1]. Addressing the emotional side of cancer is just as important as treating the physical cells. You may find it helpful to:

  • Seek reliable information: Understanding that HPV is a “background” virus of human life, and that infection timing cannot be pinpointed, can help reduce feelings of blame [5].
  • Request a multidisciplinary team: Ensure your care includes not just surgeons and oncologists, but also social workers or therapists who specialize in supporting cancer patients [1].
  • Focus on the future: Because your team knows the biology of your tumor, they have the opportunity to tailor your treatment specifically to improve the chances of a successful outcome [3].

Common questions in this guide

Does an HPV-positive result mean I caused my cervical cancer?
An HPV-positive result does not mean you caused your cancer. HPV is very common, often clears within one to two years, and can remain quiet for years; a test cannot show when it was acquired or who transmitted it. Persistent high-risk HPV can cause changes in cervical cells, but the infection is not a reflection of your choices.
What kinds of cervical cancer can appear on a pathology report?
The two most common types are squamous cell carcinoma, which starts in flat cells on the outer cervix, and adenocarcinoma, which starts in mucus-making gland cells in the cervical canal. Adenosquamous carcinoma contains both cell types. Neuroendocrine carcinoma and gastric-type adenocarcinoma are rarer and may need specialized review and care.
Why is the cell type on my cervical cancer report important?
The cell type, or histology, tells your team where the cancer started and can help them understand how it may behave. It is one part of deciding what tests, specialists, and treatment planning are appropriate. A gynecologic pathologist may be especially helpful when the tumor is rare or the findings are complex.
What does it mean if my cervical tumor tests negative for HPV?
Some cervical cancers, including gastric-type adenocarcinoma, are HPV-independent, meaning they are not caused by HPV. A negative HPV result can also need careful interpretation with the tumor’s appearance and pathology testing. Ask whether a gynecologic pathologist reviewed the result and whether another source of cancer was considered.
Will HPV status change my cervical cancer treatment?
Your doctors consider HPV status together with the cancer’s cell type, stage, and other pathology findings when planning care. HPV status can influence which treatments are considered, but it does not determine the entire plan by itself. Rare or aggressive types may require specialized care.
How can I handle shame or stress after an HPV-related diagnosis?
Feeling shame, fear, or relationship stress after a diagnosis is common, but HPV is widespread and the timing of infection usually cannot be known. Counseling, cancer support groups, and help from a social worker or therapist can provide practical and emotional support. You can also tell your care team about concerns involving fertility, intimacy, or daily life.

Get notified when new evidence is published on cervical cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Enhancing Cervical Cancer Screening: New Diagnostic Methodologies, Triage, and Risk Stratification in Prevention and Treatment.

    Kamzayeva N, Bapayeva G, Terzic M, et al.

    Life (Basel, Switzerland) 2025; (15(3)) doi:10.3390/life15030367.

    PMID: 40141711
  2. 2

    Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations.

    Hendry M, Pasterfield D, Adams R, et al.

    BMJ open 2016; (6(4)):e011205 doi:10.1136/bmjopen-2016-011205.

    PMID: 27113240
  3. 3

    Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy.

    Vonsky M, Shabaeva M, Runov A, et al.

    Biochemistry. Biokhimiia 2019; (84(7)):782-799 doi:10.1134/S0006297919070095.

    PMID: 31509729
  4. 4

    HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology.

    Hurjui RM, Hurjui IA, Buțureanu TA, et al.

    International journal of molecular sciences 2025; (26(20)) doi:10.3390/ijms262010051.

    PMID: 41155343
  5. 5

    Co-production of a conversation guide for HPV-based cervical cancer screening results communication.

    Danan ER, Woodward-Abel AB, Gowdy-Jaehnig A, et al.

    Patient education and counseling 2026; (152()):109809 doi:10.1016/j.pec.2026.109809.

    PMID: 42580245
  6. 6

    Therapeutic targeting of the HPV E7 oncoprotein: Current advances and emerging strategies.

    Gholami S, Aghbash PS, Ravanlo ZZ, et al.

    International immunopharmacology 2026; (172()):116193 doi:10.1016/j.intimp.2026.116193.

    PMID: 41570748
  7. 7

    Biological and clinical aspects of HPV-related cancers.

    Szymonowicz KA, Chen J

    Cancer biology & medicine 2020; (17(4)):864-878 doi:10.20892/j.issn.2095-3941.2020.0370.

    PMID: 33299640
  8. 8

    The Natural History of Cervical Cancer and the Case for MicroRNAs: Is Human Papillomavirus Infection the Whole Story?

    Palomino-Vizcaino G, Bañuelos-Villegas EG, Alvarez-Salas LM

    International journal of molecular sciences 2024; (25(23)) doi:10.3390/ijms252312991.

    PMID: 39684702
  9. 9

    Lymphoepithelioma epidermoid carcinoma of the uterine cervix: surgical management of an isolated case and review of the literature.

    Tenazoa-Villalobos JR, Yan-Quiroz EF, Ordoñez-Chinguel A, et al.

    Ecancermedicalscience 2025; (19()):1974 doi:10.3332/ecancer.2025.1974.

    PMID: 41333355
  10. 10

    [Focus on mucinous adenocarcinoma of the uterine cervix].

    Bonin L, Devouassoux-Shisheboran M, Golfier F

    Gynecologie, obstetrique, fertilite & senologie 2019; (47(4)):352-361 doi:10.1016/j.gofs.2019.02.006.

    PMID: 30771514
  11. 11

    Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables.

    Gadducci A, Guerrieri ME, Cosio S

    Critical reviews in oncology/hematology 2019; (135()):103-114 doi:10.1016/j.critrevonc.2019.01.006.

    PMID: 30819439
  12. 12

    Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.

    Holl K, Nowakowski AM, Powell N, et al.

    International journal of cancer 2015; (137(12)):2858-68 doi:10.1002/ijc.29651.

    PMID: 26096203
  13. 13

    Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review.

    Xing B, Guo J, Sheng Y, et al.

    Frontiers in oncology 2020; (10()):606335 doi:10.3389/fonc.2020.606335.

    PMID: 33680928
  14. 14

    Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists.

    Gadducci A, Carinelli S, Aletti G

    Gynecologic oncology 2017; (144(3)):637-646 doi:10.1016/j.ygyno.2016.12.003.

    PMID: 28057354
  15. 15

    Prenatal diagnosis and management of high-grade cervical neuroendocrine carcinoma: A case report.

    Rodríguez JSJ, Hernández JA, Gallego PA, Sarmiento CDR

    Case reports in women's health 2025; (48()):e00760 doi:10.1016/j.crwh.2025.e00760.

    PMID: 41281970
  16. 16

    Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group.

    Kojima A, Shimada M, Mikami Y, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2018; (28(1)):99-106 doi:10.1097/IGC.0000000000001145.

    PMID: 29206664
  17. 17

    The developing spectrum of gastric-type cervical glandular lesions.

    Talia KL, McCluggage WG

    Pathology 2018; (50(2)):122-133 doi:10.1016/j.pathol.2017.09.009.

    PMID: 29233547
  18. 18

    Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists.

    Stolnicu S, Park KJ, Kiyokawa T, et al.

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2021; (40(Suppl 1)):S75-S91 doi:10.1097/PGP.0000000000000751.

    PMID: 33570865
  19. 19

    Recent advances in invasive adenocarcinoma of the cervix.

    Stolnicu S, Hoang L, Soslow RA

    Virchows Archiv : an international journal of pathology 2019; (475(5)):537-549 doi:10.1007/s00428-019-02601-0.

    PMID: 31209635

This page explains cervical cancer biology, HPV, and tumor histology for educational purposes only and is not medical advice. Discuss your pathology results, treatment plan, and emotional support needs with your gynecologic oncology team.